PCK2 and fatty liver disease: Xia et al. [46] reported berberine reduced fasting glucose level via the inhibition of gluconeogenesis, via decreased PEPCK and G6Pase genes in the liver, reduced hepatic steatosis, and inhibition of FAS expression.